KA/EN
Register
Medicines reference
Search
Search
Active substance

GS-441524

Favourites

Nucleoside analogue antiviral. No registration in force in Georgia. Forms: solution, tablet.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance GS-441524
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
15 mg/kg
off-label
 Cat Feline Infectious Peritonitis, effusive; Feline Infectious Peritonitis, non-effusive; Feline Infectious Peritonitis, ocular By mouth once daily
ABCD 2026
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
Update on Treatment of Feline Infectious Peritonitis: European Advisory Board on Cat Diseases (ABCD) Guidelines
Viruses, 2026
JFMS 2026
Scientific article
A study or review published in a scientific journal. Its findings apply to the animals and conditions it studied.
Legal treatment of feline infectious peritonitis in the Netherlands
Journal of Feline Medicine and Surgery, 2026
20 mg/kg
off-label
 Cat Feline Infectious Peritonitis, ocular By mouth once daily
ABCD 2026
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
Update on Treatment of Feline Infectious Peritonitis: European Advisory Board on Cat Diseases (ABCD) Guidelines
Viruses, 2026
10 mg/kg
off-label
 Cat Feline Infectious Peritonitis, neurological By mouth 2 times daily
FelineVMA 2025
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
2025 FIP Update Guide - treatment protocols by FIP type
Feline Veterinary Medical Association, 2025
10–12 mg/kg
off-label
 Cat Feline Infectious Peritonitis, effusive; Feline Infectious Peritonitis, non-effusive By mouth once daily
JFMS 2026
Scientific article
A study or review published in a scientific journal. Its findings apply to the animals and conditions it studied.
Legal treatment of feline infectious peritonitis in the Netherlands
Journal of Feline Medicine and Surgery, 2026
18–22 mg/kg
off-label
 Cat Feline Infectious Peritonitis, non-effusive By mouth once daily
JFMS 2026
Scientific article
A study or review published in a scientific journal. Its findings apply to the animals and conditions it studied.
Legal treatment of feline infectious peritonitis in the Netherlands
Journal of Feline Medicine and Surgery, 2026
6–8 mg/kg
off-label
 Cat Feline Infectious Peritonitis, effusive Subcutaneous once daily
Jones et al. 2021
Scientific article
A study or review published in a scientific journal. Its findings apply to the animals and conditions it studied.
Unlicensed GS-441524-Like Antiviral Therapy Can Be Effective for at-Home Treatment of Feline Infectious Peritonitis
Viruses, 2021
8–10 mg/kg
off-label
 Cat Feline Infectious Peritonitis, non-effusive Subcutaneous once daily
Jones et al. 2021
Scientific article
A study or review published in a scientific journal. Its findings apply to the animals and conditions it studied.
Unlicensed GS-441524-Like Antiviral Therapy Can Be Effective for at-Home Treatment of Feline Infectious Peritonitis
Viruses, 2021
12–15 mg/kg
off-label
 Cat Feline Infectious Peritonitis, ocular; Feline Infectious Peritonitis, neurological Subcutaneous once daily
Jones et al. 2021
Scientific article
A study or review published in a scientific journal. Its findings apply to the animals and conditions it studied.
Unlicensed GS-441524-Like Antiviral Therapy Can Be Effective for at-Home Treatment of Feline Infectious Peritonitis
Viruses, 2021
Before use

Safety information

Known Contraindications

  • Critical
    Antivirals are not licenced in cats and are still not available legally in all countries, complicating their use. veterinary special
    Source: EMA Sources: VMD · FDA · EU UPD
  • Warning (Cat)
    might long-FIP
  • Warning (Cat)
    Mild to moderate transient increases in liver enzymes have been reported during GS-441524 treatment, but their clinical significance and causal relationship to the drug are uncertain because feline infectious peritonitis itself may contribute. Monitor liver enzymes during treatment.
  • Warning (Cat)
    pregnancy
  • Warning (Cat)
    lactation
  • Warning (Cat)
    If the dose is not adjusted, underdosage occurs, which can be associated with disease relapse.
  • Caution (Cat)
    possible kidney disease
Latin name
GS-441524
Georgian name
GS-441524
Authorisation status
No authorisation anywhere
Not authorised as a veterinary or a human medicine in any register checked.
Registered in Georgia
0 of 2 forms
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration2

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

GS-441524 30 mg/ml, Solution

solution for injection, compounded veterinary special
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
Not rateable
No numerical score assigned
vetman assessment

GS-441524 30 mg/ml

solution for injection, compounded veterinary special
Assessed clinical scopeCat · Treatment of confirmed or very-high-probability feline infectious peritonitis with the listed compounded presentation · SC,IV
Care settingVeterinarian-directed FIP treatment with legal procurement, formulation verification, response-led dosing and serial clinical/laboratory monitoring
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: No · Verified on 22 Oct 2026 Off-label use
Not rateable

GS-441524 has strong and current feline FIP efficacy evidence, but this anonymous 30 mg/ml injectable is not an exact assessable product: it names no compounder, formulation, excipients, sterility/endotoxin or pH/osmolality specification, batch assay, pack, legal supply endpoint or preparation-specific instruction. Its former SC regimen was a clinic-created scheme within an observational range, not a validated exact-product dose, and no oral-to-injectable conversion exists. Current guidance generally favours oral GS-441524 and uses IV remdesivir—not anonymous GS-441524 injection—for selected critically ill cats. Numerical axes would therefore rate the molecule while pretending to rate an unknown injectable.

The antiviral concept is evidence-based; this anonymous injectable is not. Do not inject or calculate from the listed concentration until a named legal preparation, traceable specification, sterility/assay evidence and route-specific instruction are attached.

Important safety and use flags

  • This is a product-identity failure, not a rejection of GS-441524 treatment. Current ABCD/FelineVMA guidance and clinical studies support GS-441524 for feline FIP, but the evidence applies to identified/studied preparations and substance regimens.
  • The row identifies no compounder, trade name, current formulation specification, batch assay/certificate, excipients, pack or legal supply endpoint. “Compounded veterinary special” is a category, not an exact product identity.
  • Do not assume this solution contains 30 mg/ml or is sterile, endotoxin-controlled, physiologically tolerable or stable after opening. Obtain the named compounder’s specification, assay, sterility/endotoxin record and handling instruction.
  • No exact-product SC or IV dose is published. The removed SC ranges were a clinic-created protocol, not a label or validated oral-to-injectable conversion; current IV guidance mainly concerns remdesivir.
  • Unlicensed-product testing found frequent material differences from declared GS-441524 content. Legal sourcing, GMP-capable compounding, traceable batch documentation and clinical response monitoring are safety-critical, not administrative niceties.
  • Confirm FIP to a high probability and actively review differentials. A rapid response can support but does not replace diagnosis; failure to improve within about 48 hours requires reassessing diagnosis, formulation authenticity, dose delivery and complications.
  • Monitor weight and recalculate frequently in growing or recovering cats; underdosing can follow rapid weight gain. Track clinical status, effusion, haematology, bilirubin, albumin/globulin and liver/renal markers before stopping.
  • SC GS-441524 can be markedly painful and cause injection-site reactions. Do not use an anonymous injectable; current guidance generally reserves IV remdesivir for severely ill cats unable to tolerate oral therapy.
  • GS-441524 is not an authorised veterinary medicine in GE/EU/GB/US. Legal compounding or enforcement-discretion pathways are jurisdiction-specific and do not equal product approval; document the prescription, source and informed consent.
  • Pregnancy/lactation, very young kittens, long-term recurrence/resistance and delayed adverse effects remain incompletely characterised. Monitor ALT/renal markers and investigate persistent weight loss, anorexia, vomiting, lymphadenopathy or other relapse/neoplasia signals.
Assessment sources
  1. ABCD FIP 20262026
  2. FelineVMA FIP 20252025
  3. Original GS-441524 trial2019
  4. GS-441524 duration RCT2024
  5. Netherlands legal FIP cohort2026
  6. GS-441524 content analysis2024
  7. GS-441524 TDM/formulation analysis2026
  8. FDA GS-441524 compounding position2024
  9. GE GS-441524 register audit2026
  10. VMD GS-441524 authorisation audit2026
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
GS-44152430 mg/ml
Formulation Type
Solution
Administration route
Subcutaneous, Intravenous
Manufacturer
-
Product
generic presentation, not registered in Georgia under a trade name
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 22 Oct 2026
 EU No
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No SC or IV dose is established for this exact preparation because no compounder, formulation, batch assay, sterility/endotoxin specification, excipients, pH/osmolality, pack or legal supply endpoint is identified. Do not publish the clinic-created SC schedule or infer an oral-to-injectable conversion. Current guidance generally favours oral GS-441524 and reserves IV injectable remdesivir for selected severely ill cats.

GS-441524 50 mg, Tablet

tablet, compounded veterinary special
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
Not rateable
No numerical score assigned
vetman assessment

GS-441524 50 mg

tablet, compounded veterinary special
Assessed clinical scopeCat · Treatment of confirmed or very-high-probability feline infectious peritonitis with the listed compounded presentation · By mouth
Care settingVeterinarian-directed FIP treatment with legal procurement, formulation verification, response-led dosing and serial clinical/laboratory monitoring
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: No · Verified on 22 Oct 2026 Off-label use
Not rateable

GS-441524 has strong and current feline FIP efficacy evidence, including consensus guidance and controlled/large cohort data. This catalogue row is not an exact assessable product: it names no compounder, trade name, formulation, excipients, batch assay/content-uniformity or dissolution specification, pack, legal supply endpoint or preparation-specific instruction. Published testing shows that unlicensed products can differ materially from declared content. A legal compounded 50 mg tablet from a named quality-controlled supplier could be assessed separately, but efficacy and safety cannot be transferred to this anonymous row; even quartering/crushing and actual 50 mg content are unverified.

The treatment concept is evidence-based; the listed product is not identifiable. Replace this generic placeholder with a named, legally supplied, traceable compounded preparation before assigning a product score or exact-product dose.

Important safety and use flags

  • This is a product-identity failure, not a rejection of GS-441524 treatment. Current ABCD/FelineVMA guidance and clinical studies support GS-441524 for feline FIP, but the evidence applies to identified/studied preparations and substance regimens.
  • The row identifies no compounder, trade name, current formulation specification, batch assay/certificate, excipients, pack or legal supply endpoint. “Compounded veterinary special” is a category, not an exact product identity.
  • Do not assume this tablet contains 50 mg, is scored, can be quartered or crushed, or has the dissolution/bioavailability of a named legal preparation. Obtain the compounder’s current specification and batch documentation.
  • No exact-product dose is published. Use current FIP guidance only after selecting a named legal oral preparation; dose by FIP form, current weight and response, and verify actual strength and measurable unit.
  • Unlicensed-product testing found frequent material differences from declared GS-441524 content. Legal sourcing, GMP-capable compounding, traceable batch documentation and clinical response monitoring are safety-critical, not administrative niceties.
  • Confirm FIP to a high probability and actively review differentials. A rapid response can support but does not replace diagnosis; failure to improve within about 48 hours requires reassessing diagnosis, formulation authenticity, dose delivery and complications.
  • Monitor weight and recalculate frequently in growing or recovering cats; underdosing can follow rapid weight gain. Track clinical status, effusion, haematology, bilirubin, albumin/globulin and liver/renal markers before stopping.
  • Oral GS-441524 is generally preferred when feasible. Administration with an empty stomach or small treat and a feeding interval is guidance-dependent; follow the exact legal preparation’s instruction and verify full ingestion.
  • GS-441524 is not an authorised veterinary medicine in GE/EU/GB/US. Legal compounding or enforcement-discretion pathways are jurisdiction-specific and do not equal product approval; document the prescription, source and informed consent.
  • Pregnancy/lactation, very young kittens, long-term recurrence/resistance and delayed adverse effects remain incompletely characterised. Monitor ALT/renal markers and investigate persistent weight loss, anorexia, vomiting, lymphadenopathy or other relapse/neoplasia signals.
Assessment sources
  1. ABCD FIP 20262026
  2. FelineVMA FIP 20252025
  3. Original GS-441524 trial2019
  4. GS-441524 duration RCT2024
  5. Netherlands legal FIP cohort2026
  6. GS-441524 content analysis2024
  7. GS-441524 TDM/formulation analysis2026
  8. FDA GS-441524 compounding position2024
  9. GE GS-441524 register audit2026
  10. VMD GS-441524 authorisation audit2026
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
GS-44152450 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
-
Product
generic presentation, not registered in Georgia under a trade name
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 22 Oct 2026
 EU No
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dose is established for this exact preparation because no compounder, formulation, batch assay, excipients, dissolution specification, pack or legal supply endpoint is identified. Current feline FIP guidance supports oral GS-441524 as a substance, but do not assume that this anonymous tablet contains 50 mg, is score-equivalent, can be quartered/crushed or matches a studied/legal formulation.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 25 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗